5-EAPB: Extremely limited human data; doses above 140 mg strongly discouraged. Fatal case reported at ~500 mg combined with MDAI (blood concentration 6.45 mg/L). Acts as monoamine releasing agent with 5-HT2A/5-HT2B agonist properties; chronic use may risk valvular heart disease via 5-HT2B activation
Related pages